Welcome to our dedicated page for Inspire Medical news (Ticker: INSP), a resource for investors and traders seeking the latest updates and insights on Inspire Medical stock.
Inspire Medical Systems, Inc. (NYSE: INSP) is a medical technology company focused on minimally invasive neurostimulation therapy for patients with obstructive sleep apnea. This news page aggregates company announcements, clinical updates, and financial disclosures so readers can follow how Inspire therapy and the Inspire V system are progressing in clinical practice and the marketplace.
Inspire regularly issues earnings releases and financial guidance, including preliminary and unaudited revenue ranges, full-year outlooks, and discussions of non-GAAP measures such as adjusted net income and adjusted EBITDA. Investors can track how revenue tied to Inspire therapy evolves over time, as well as information about share repurchase authorizations and tax-related items disclosed in Form 8-K filings and accompanying press releases.
Because Inspire’s core business is neurostimulation-based treatment for moderate to severe obstructive sleep apnea, a significant portion of its news flow centers on clinical data and product evolution. The company publishes outcomes from studies of the Inspire V system, including procedure success rates, reductions in disease severity, and patient adherence, and presents these results at medical meetings such as the American Academy of Otolaryngology–Head and Neck Surgery and the International Surgical Sleep Society.
Corporate governance and leadership changes are also covered, including announcements about the transition of the Chief Financial Officer role, executive employment agreements, and retirement plans for senior leaders. In addition, Inspire frequently reports on its participation in major healthcare and investor conferences, where management discusses business performance, reimbursement developments, and strategic priorities.
By reviewing this news feed, followers of INSP stock can see how Inspire communicates its financial performance, clinical evidence, regulatory and reimbursement context, and leadership decisions over time, all drawn from company-issued releases and related SEC filings.
Inspire Medical Systems, Inc. (NYSE: INSP) has received CE Mark certification for full-body MRI compatibility under the European Union's Medical Device Regulation. This approval expands the use of Inspire therapy, allowing patients with the Inspire IV neurostimulator to undergo full-body MRI scans, in addition to previously approved head, neck, and extremity scans. The certification applies retroactively to all patients with the device implanted since 2018.
This milestone enhances Inspire's ability to serve patients with obstructive sleep apnea (OSA) who struggle with CPAP. The full-body MRI compatibility, already available in the United States for two years, addresses a significant barrier for potential patients concerned about future access to MRI diagnostics. Inspire has conducted extensive testing to ensure safe performance in 1.5T MRI environments.
Inspire Medical Systems (NYSE: INSP) announced it will release its second quarter 2024 financial results on August 6, 2024, after market close. Following the release, the management team will host a conference call at 5:00 p.m. Eastern Time to discuss results and recent business developments. The webcast will be accessible via Inspire's Investor Relations page. Questions for management can be submitted through a provided registration link, which will generate a unique access code for the live call. A replay of the call will be available approximately two hours after the event and will remain accessible for two weeks on the company's website.
Inspire Medical Systems (NYSE: INSP) will present at the Truist Securities Medtech Conference on June 18, 2024, at 10:40 a.m. ET. The company specializes in minimally invasive solutions for obstructive sleep apnea. The presentation will be accessible via a live webcast, with a replay available for two weeks on Inspire's investor website.
Inspire Medical Systems, a medical technology company specializing in innovative, minimally invasive solutions for obstructive sleep apnea, announced its participation in the Jefferies Global Healthcare Conference. Scheduled for June 6, 2024, at 11:30 a.m. Eastern Time, the presentation will be accessible via a live webcast with a replay available for two weeks on Inspire’s Investor website.
Inspire Medical Systems, Inc. reported a 28% year-over-year revenue growth in the first quarter of 2024, reaching $164.0 million. The company expects profitability for the full year 2024, increasing revenue guidance to $783 million to $793 million, reflecting growth of 25% to 27% over 2023. With improved outlook and strong performance, Inspire is optimistic about the remainder of 2024.
Inspire Medical Systems, a medical technology company specializing in solutions for obstructive sleep apnea, will present at the BofA Securities 2024 Health Care Conference on May 14, 2024. The presentation will be live-streamed and available for replay on Inspire's Investor website.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Inspire Medical (INSP)?
What is the market cap of Inspire Medical (INSP)?
